Avalon GloboCare Corp. Stock News

Gainers Petros Pharmaceuticals, Inc. (NASDAQ: PTPI) gained 231% to $2.63 on news that the company will be acquired By Henry Crown and Company for $3.25 per share. Petros Pharmaceuticals, however, con

Gainers JAKKS Pacific, Inc. (NASDAQ: JAKK) rose 34.7% to $23.01 in pre-market trading after the company reported better-than-expected Q2 results. Athersys, Inc. (NASDAQ: ATHX) rose 35.1% to $0.2568 i

Avalon GloboCare Corp (NASDAQ:AVCO) announced a new study incorporating artificial intelligence (AI)-enhanced protein design technology that could accelerate development of therapeutic monoclonal anti

FREEHOLD, N.J., May 25, 2022 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO), a leading global developer of innovative cell-based technologies and therapeutics, announced today that David Ji

Avalon GloboCare Corp (NASDAQ:AVCO) has signed a memorandum of understanding with Lu Daopei Hematology Institute (LDHI) to co-develop precision companion diagnostics for chimeric antigen receptor (CAR

Avalon GloboCare Corp (NASDAQ:AVCO) has revealed that is has filed 16 patent applications related to novel cellular therapies and related technologies as the company moves towards clinical trials. The

Avalon GloboCare Corp (NASDAQ: AVCO ) is expanding its cellular immuno-oncology program with the addition of novel Chimeric Antigen Receptor – Natural Killer (CAR-NK) cell therapies . Avalon is leveraging its mRNA-based FLASH-CAR platform to develop autologous and universal CAR-NK technology and cellular therapies for … Full story available on Benzinga.com

FREEHOLD, N.J., Feb. 14, 2022 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO), a leading global developer of cell-based technologies and therapeutics, announced today that the Company is e

Avalon GloboCare Corp (NASDAQ: AVCO) is expanding its cellular immuno-oncology program with the addition of novel Chimeric Antigen Receptor – Natural Killer (CAR-NK) cell therapies. Avalon is leve

Avalon GloboCare Corp (NASDAQ:AVCO) said it is expanding its cellular immuno-oncology program with the addition of novel Chimeric Antigen Receptor-Natural Killer (CAR-NK) cell therapies. Natural kille

Avalon GloboCare Corp (AVCO) shares closed 5.0% lower than its previous 52 week low, giving the company a market cap of $68M. The stock is currently down 3.0% year-to-date, down 29.6% over the past 12 months, and down 69.5% over the past five years. This week, the Dow Jones Industrial Average fell 0.2%, and the S&P 500 fell 1.9%. Trading Activity Trading volume this week was 67.0% lower than the 20-day average.Beta, a measure of the stock’s volatility relative to the overall market stands at 1.5. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -240.3% The company's stock price performance over the past 12 months lags the peer average by -211.8% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Avalon GloboCare Corp (NASDAQ:AVCO) told investors it was 'well positioned' to execute on its growth strategy this year as the company highlighted it had partnered with world-renowned research centers

Avalon GloboCare Corp (NASDAQ:AVCO) announced that it has further advanced its research to accurately predict the 3-dimensional structures of protein receptors for potential use as cellular therapy t

Avalon GloboCare Corp. has successfully co-developed a novel platform of S-layer coated emulsome technology (SLET) for next-generation drug delivery and cellular immunotherapy.

FREEHOLD, N.J., Oct. 14, 2021 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO) (Avalon or The Company), a clinical-stage global developer of cell-based technologies and therapeutics, today an